PLTR News: Palantir Technologies continues decline but manages to hold support
Premium|Take advantage of 75% OFF on your first month.
Grab this special offer, it's a 1 year for FREE deal! And access ALL our articles and analysis.
You have reached your limit of 5 free articles for this month.
BLACK FRIDAY SALE! 75% OFF!
Grab this special offer, it's a 1 year for FREE deal! And access ALL our articles and analysis.
CLAIM OFFER- NYSE:PLTR fell by a further 1.13% on Friday despite the broader markets closing the week higher.
- Palantir appoints a U.K. managing director as it furthers its reach into Europe.
- Palantir continues to be a strong PIPE investor into upcoming SPAC mergers.
NYSE:PLTR closed the week before July 4th on a downtrend, although the stock did manage to stay above a key support level of $24.00. On Friday, shares of Palantir dipped a further 1.13% to close the trading session at $24.44, which can be seen as positive as it stayed above its 21-day moving average price. If Palantir continues to decline into next week, the stock could lose that support and all of the gains that were made over the past month could be lost. Palantir continues to be a popular stock for institutional and retail investors alike, with strong support from Reddit forums such as r/WallStreetBets, as well as popular funds like Ark Invest.
Stay up to speed with hot stocks' news!
Palantir took another step closer to solidifying its presence in Europe and the U.K. by appointing Dr. Justin Whatling as the new managing director of Palantir’s European portfolio. The data analytics company established a significant partnership with the NHS or National Health Service of England, and the hiring of Dr. Whatling will look to continue this strong relationship in the years ahead.
PLTR stock forecast
Palantir has been active with its own investing as well in recent months. The company has been acting as a PIPE investor for several high profile SPAC mergers that are in the works, including some that it already has contracts with for data analytics services. Some of the names include Lilium which is an eVTOL taxi business and Sarcos Robotics, an industrial robotics company that has investors such as Blackrock and Caterpillar Venture Capital.
- NYSE:PLTR fell by a further 1.13% on Friday despite the broader markets closing the week higher.
- Palantir appoints a U.K. managing director as it furthers its reach into Europe.
- Palantir continues to be a strong PIPE investor into upcoming SPAC mergers.
NYSE:PLTR closed the week before July 4th on a downtrend, although the stock did manage to stay above a key support level of $24.00. On Friday, shares of Palantir dipped a further 1.13% to close the trading session at $24.44, which can be seen as positive as it stayed above its 21-day moving average price. If Palantir continues to decline into next week, the stock could lose that support and all of the gains that were made over the past month could be lost. Palantir continues to be a popular stock for institutional and retail investors alike, with strong support from Reddit forums such as r/WallStreetBets, as well as popular funds like Ark Invest.
Stay up to speed with hot stocks' news!
Palantir took another step closer to solidifying its presence in Europe and the U.K. by appointing Dr. Justin Whatling as the new managing director of Palantir’s European portfolio. The data analytics company established a significant partnership with the NHS or National Health Service of England, and the hiring of Dr. Whatling will look to continue this strong relationship in the years ahead.
PLTR stock forecast
Palantir has been active with its own investing as well in recent months. The company has been acting as a PIPE investor for several high profile SPAC mergers that are in the works, including some that it already has contracts with for data analytics services. Some of the names include Lilium which is an eVTOL taxi business and Sarcos Robotics, an industrial robotics company that has investors such as Blackrock and Caterpillar Venture Capital.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.